It has been identified using tumor-associated lymphocytes isolated from patients with ovarian and breast cancers [12] and a GP2 peptide vaccine is currently being evaluated in a phase II efficacy trial enrolling breast cancer patients [13]. This evidence concerns the gene GP2 and breast carcinoma.